Literature DB >> 2263897

The epidemiology of trachoma predicts more blindness in the future.

J Schachter1, C R Dawson.   

Abstract

Trachoma is considered the world's leading preventable cause of blindness, with hundreds of millions of people affected and approximately 6 to 9 million blinded as a result of the disease. It was once endemic in much of the world. It disappeared from most of Europe and North America, coincident with the improvements in hygienic conditions that accompanied the expanding industrial revolution in the latter part of the 19th century. Common wisdom states that trachoma is disappearing from much of the world today as a result of improvement in the standard of living. Unfortunately, this is not a realistic perception. In some hyperendemic areas neither the standard of living nor hygienic conditions are improving. Deaths due to acute infections have been reduced and the population is both growing and aging. In some parts of the world, because of demographics, it is likely that there are more people being exposed to trachoma as children and more will survive to old age when trachomatous blindness develops. In these countries there will be larger numbers of blind individuals in the future than there are today. This will tax public health and economic systems in the involved communities.

Entities:  

Mesh:

Year:  1990        PMID: 2263897

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  21 in total

Review 1.  Eradication of trachoma worldwide.

Authors:  D Mabey; R Bailey
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Genome sequencing and our understanding of chlamydiae.

Authors:  D D Rockey; J Lenart; R S Stephens
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Failure to detect HLA-A*6802-restricted CD8+ T cells specific for Chlamydia trachomatis antigens in subjects from trachoma-endemic communities.

Authors:  O S Mahdi; H C Whittle; H Joof; D C Mabey; R L Bailey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

4.  Chlamydiaphage Chp2, a skeleton in the phiX174 closet: scaffolding protein and procapsid identification.

Authors:  Ian N Clarke; Leslie T Cutcliffe; J Sylvia Everson; Sarah A Garner; Paul R Lambden; Paddy J Pead; Mark A Pickett; Karie L Brentlinger; Bentley A Fane
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

5.  Characterizing the intracellular distribution of metabolites in intact Chlamydia-infected cells by Raman and two-photon microscopy.

Authors:  Márta Szaszák; Jiun Chiun Chang; Weinan Leng; Jan Rupp; David M Ojcius; Anne Myers Kelley
Journal:  Microbes Infect       Date:  2013-03-27       Impact factor: 2.700

6.  Differential interaction with endocytic and exocytic pathways distinguish parasitophorous vacuoles of Coxiella burnetii and Chlamydia trachomatis.

Authors:  R A Heinzen; M A Scidmore; D D Rockey; T Hackstadt
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Fusion of Chlamydia trachomatis-containing inclusions is inhibited at low temperatures and requires bacterial protein synthesis.

Authors:  C Van Ooij; E Homola; E Kincaid; J Engel
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

Review 8.  The global burden of trachoma: a review.

Authors:  Matthew J Burton; David C W Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-10-27

9.  Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle.

Authors:  Rachel J Skilton; Lesley T Cutcliffen; David Barlow; Yibing Wang; Omar Salim; Paul R Lambden; Ian N Clarke
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

10.  Innate immunity in ocular Chlamydia trachomatis infection: contribution of IL8 and CSF2 gene variants to risk of trachomatous scarring in Gambians.

Authors:  Angels Natividad; Jeremy Hull; Gaia Luoni; Martin Holland; Kirk Rockett; Hassan Joof; Matthew Burton; David Mabey; Dominic Kwiatkowski; Robin Bailey
Journal:  BMC Med Genet       Date:  2009-12-16       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.